Tags

Type your tag names separated by a space and hit enter

Disease-modifying drugs for multiple sclerosis: current and future aspects.
Expert Opin Pharmacother 2006; 7 Suppl 1:S1-9EO

Abstract

Multiple sclerosis (MS) is the most common inflammatory demyelinating disorder of the human CNS, affecting an estimated 2.5 million people in the world. Until the 1990s, treatment was mainly symptomatic, but a new era began with the introduction of disease-modifying therapy that seems to alter the natural course of MS. Current drugs include three interferons (IFNs): IFN-beta1a (Avonex intramuscular; Biogen, Cambridge, USA; Rebif subcutaneous; Serono, Geneva, Switzerland), IFN-beta1b (Betaseron subcutaneous; Schering, Berlin, Germany) and glatiramer acetate (Copaxone subcutaneous; Teva, Petach Tikva, Israel). Ongoing research targeting a variety of mechanisms and processes means there is much promise for the future treatment of MS.

Authors+Show Affiliations

University of Ottawa and Ottawa Health Research Institute, Canada. mfreedman@ottawahospital.on.ca.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17020427

Citation

Freedman, Mark S.. "Disease-modifying Drugs for Multiple Sclerosis: Current and Future Aspects." Expert Opinion On Pharmacotherapy, vol. 7 Suppl 1, 2006, pp. S1-9.
Freedman MS. Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opin Pharmacother. 2006;7 Suppl 1:S1-9.
Freedman, M. S. (2006). Disease-modifying drugs for multiple sclerosis: current and future aspects. Expert Opinion On Pharmacotherapy, 7 Suppl 1, pp. S1-9.
Freedman MS. Disease-modifying Drugs for Multiple Sclerosis: Current and Future Aspects. Expert Opin Pharmacother. 2006;7 Suppl 1:S1-9. PubMed PMID: 17020427.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Disease-modifying drugs for multiple sclerosis: current and future aspects. A1 - Freedman,Mark S, PY - 2006/10/6/pubmed PY - 2006/11/15/medline PY - 2006/10/6/entrez SP - S1 EP - 9 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 7 Suppl 1 N2 - Multiple sclerosis (MS) is the most common inflammatory demyelinating disorder of the human CNS, affecting an estimated 2.5 million people in the world. Until the 1990s, treatment was mainly symptomatic, but a new era began with the introduction of disease-modifying therapy that seems to alter the natural course of MS. Current drugs include three interferons (IFNs): IFN-beta1a (Avonex intramuscular; Biogen, Cambridge, USA; Rebif subcutaneous; Serono, Geneva, Switzerland), IFN-beta1b (Betaseron subcutaneous; Schering, Berlin, Germany) and glatiramer acetate (Copaxone subcutaneous; Teva, Petach Tikva, Israel). Ongoing research targeting a variety of mechanisms and processes means there is much promise for the future treatment of MS. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/17020427/full_citation L2 - http://www.tandfonline.com/doi/full/10.1517/14656566.7.1.S1 DB - PRIME DP - Unbound Medicine ER -